{"entity":{"id":"talia-golan","kind":"person","name":"Talia Golan","aka":[],"tldr":"Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.","summary":"Talia Golan was principal investigator and first author of POLO, which showed maintenance olaparib nearly doubles progression-free survival in germline BRCA-mutant metastatic pancreatic cancer after platinum chemotherapy, the first targeted therapy approval in the disease. She directs the pancreatic cancer centre at Sheba and works on organoid-guided therapy and DNA damage response combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib"}],"tags":["pancreatic","parp","brca"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["parp-inhibitor","organoids"],"targets":["parp","brca"],"drugs":["olaparib"],"companies":[],"institutions":["sheba"],"pathways":[],"terms":[],"trials":["polo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Pancreatic Cancer Center, Sheba Medical Center","institutionId":"sheba","specialisms":["Pancreatic cancer","BRCA-associated cancer","PARP inhibitors","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib"}],"papers":[{"title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903387"},{"title":"Overall survival from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.01604"}]},"route":"/people/talia-golan/","neighbours":{"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/"}],"trial":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/"}],"paper":[{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/"},{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/"},{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/"},{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/"},{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/"},{"id":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","kind":"paper","name":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","route":"/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]}}